科研速览 · Science Skim继续刷下去 · Keep skimming →
◆ Journal of diabetes science and technology2026-08-25

Bridging the Digital Divide: Real-World Efficacy of Commercial and Open-Source Automated Insulin Delivery Systems in a Diverse, Low-Resource Pediatric Population.

Karin Dreifuss, Floris Levy-Khademi, Carmit Avnon Ziv, Adi Auerbach

一句话结论 · In one sentence

In a heterogeneous real-world pediatric cohort including a low-resource population with limited technological access, both AID systems significantly improved glycemic outcomes without compromising safety. These findings suggest AID benefits transcend socioeconomic barriers, supporting patient autonomy in system selection.

原始摘要(英文原文)· Original abstract
BACKGROUND: Achieving optimal glycemic control in type 1 diabetes (T1D) is challenging. Automated insulin delivery (AID) systems have improved outcomes, yet data on open-source systems-particularly in low-resource, low technological literacy settings-remain limited. This study compared the efficacy and safety of an open-source system with a regulatory-approved system in a heterogeneous real-world pediatric cohort. METHODS: This longitudinal observational study included 61 children with T1D treated at Shaare Zedek Medical Center: 30 using the regulatory-approved Medtronic 780G and 31 using the open-source AndroidAPS AID system. Socioeconomic status (SES) was determined by residential address. Glycemic outcomes were compared between AID use and prior sensor-augmented pump therapy. Primary endpoints included changes in time in range (TIR), average glucose, glucose management indicator (GMI), and hypoglycemia/hyperglycemia duration. Safety outcomes included rates of severe hypoglycemia and diabetic ketoacidosis (DKA). RESULTS: Both groups demonstrated significant glycemic improvements after transitioning to AID, including an increase in %TIR (56.6 ± 14.1 vs 69.3 ± 8.8) and reduction in average blood glucose (173.3 ± 31.7 vs 149.9 ± 18.3), GMI and % time in hyperglycemia. No significant differences in glycemic outcomes were observed between groups, although a trend toward greater reduction in average blood glucose and GMI was observed in the regulatory-approved group. No episodes of severe hypoglycemia or DKA occurred in either group. CONCLUSIONS: In a heterogeneous real-world pediatric cohort including a low-resource population with limited technological access, both AID systems significantly improved glycemic outcomes without compromising safety. These findings suggest AID benefits transcend socioeconomic barriers, supporting patient autonomy in system selection.
读原文 · Read the paper ↗

AI 追问PRO

登录后使用 AI 追问

讨论区

登录后参与讨论

相关论文 · Related

Bridging the Digital Divide: Real-World Efficacy of Commercial and Open-Source Automated Insulin Delivery Systems in a Diverse, Low-Resource Pediatric Population. — 科研速览 Science Skim